DK0842661T3 - Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning - Google Patents

Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning

Info

Publication number
DK0842661T3
DK0842661T3 DK97308862T DK97308862T DK0842661T3 DK 0842661 T3 DK0842661 T3 DK 0842661T3 DK 97308862 T DK97308862 T DK 97308862T DK 97308862 T DK97308862 T DK 97308862T DK 0842661 T3 DK0842661 T3 DK 0842661T3
Authority
DK
Denmark
Prior art keywords
manufacture
atherosclerosis
antagonists
drug
independent
Prior art date
Application number
DK97308862T
Other languages
English (en)
Inventor
Robert Joseph Aiello
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0842661T3 publication Critical patent/DK0842661T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J47/00—Kitchen containers, stands or the like, not provided for in other groups of this subclass; Cutting-boards, e.g. for bread
    • A47J47/02—Closed containers for foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
DK97308862T 1996-11-15 1997-11-05 Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning DK0842661T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3127396P 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
DK0842661T3 true DK0842661T3 (da) 2001-09-24

Family

ID=21858549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97308862T DK0842661T3 (da) 1996-11-15 1997-11-05 Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning

Country Status (17)

Country Link
US (1) US6034102A (da)
EP (1) EP0842661B1 (da)
JP (1) JP3287793B2 (da)
KR (1) KR100367793B1 (da)
AT (1) ATE202702T1 (da)
AU (1) AU740378B2 (da)
CA (1) CA2221114C (da)
DE (1) DE69705480T2 (da)
DK (1) DK0842661T3 (da)
ES (1) ES2158452T3 (da)
GR (1) GR3036455T3 (da)
HU (1) HU223942B1 (da)
IL (1) IL122123A (da)
MY (1) MY114586A (da)
NZ (1) NZ329174A (da)
PT (1) PT842661E (da)
ZA (1) ZA9710292B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US20020037311A1 (en) * 2000-06-01 2002-03-28 David Fikstad Transdermal delivery of lasofoxifene
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
CN100577174C (zh) 2000-11-24 2010-01-06 脉管生物生长有限公司 含有限定的氧化磷脂的组合物
AU2002221116A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
WO2002062296A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
ES2330731T3 (es) * 2001-08-30 2009-12-15 Chemocentryx, Inc. Compuestos biciclicos como inhibidores de la union de quimioquina a us28.
DE602005022924D1 (de) * 2004-12-08 2010-09-23 Cedars Sinai Medical Ct Los An Verfahren zur diagnose von morbus crohn
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
EP2978440B1 (en) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4320898A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
KR19980042432A (ko) 1998-08-17
AU4523797A (en) 1998-05-21
GR3036455T3 (en) 2001-11-30
NZ329174A (en) 2000-10-27
JPH10147527A (ja) 1998-06-02
JP3287793B2 (ja) 2002-06-04
US6034102A (en) 2000-03-07
AU740378B2 (en) 2001-11-01
CA2221114C (en) 2003-10-28
DE69705480D1 (de) 2001-08-09
HUP9702040A1 (hu) 2000-11-28
KR100367793B1 (ko) 2003-04-21
ATE202702T1 (de) 2001-07-15
HU223942B1 (hu) 2005-03-29
IL122123A (en) 2001-07-24
CA2221114A1 (en) 1998-05-15
HU9702040D0 (en) 1998-01-28
MY114586A (en) 2002-11-30
EP0842661A3 (en) 1998-09-02
EP0842661B1 (en) 2001-07-04
EP0842661A2 (en) 1998-05-20
IL122123A0 (en) 1998-04-05
ES2158452T3 (es) 2001-09-01
PT842661E (pt) 2001-10-30
DE69705480T2 (de) 2001-10-31
ZA9710292B (en) 1999-05-17

Similar Documents

Publication Publication Date Title
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
DE68906183D1 (de) 2'-desoxy-5-fluoruridinderivate.
MX9202844A (es) 1-indolilalquil-4-( alcoxi-pirimidinil) piperazinas y composicion farmaceutica que las contiene.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
PT1468692E (pt) Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma
DK0807627T3 (da) Anilidforbindelser som ACAT-inhibitorer
FI915653A (fi) 5-amino-5,6,7,8-tetrahydroquinoliner och beslaektade foereningar, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DE69017627T2 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
FI954213A0 (fi) Kasvainten vastaisia koostumuksia ja hoitomenetelmiä
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
AR023572A1 (es) Derivados de tetrahidroisoquinolinil-indol para el tratamiento de la depresion y composicion farmaceutica que los comprende